Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NYSE MKT | Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases.
The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.
In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells.
It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 7, 25 | -0.48 Increased by +89.20% | - |
| Nov 12, 24 | -0.46 Decreased by -92.78% | -0.48 Increased by +3.73% |
| Sep 25, 24 | -0.90 Decreased by -446.88% | -0.47 Decreased by -91.89% |
| May 13, 24 | -0.85 Decreased by -54.43% | - |
| Feb 9, 24 | -4.42 Decreased by -309.63% | - |
| Nov 13, 23 | -0.24 Increased by +87.77% | - |
| Sep 27, 23 | 0.26 Increased by +113.27% | -0.41 Increased by +163.41% |
| May 15, 23 | -0.55 Increased by +63.12% | -0.36 Decreased by -53.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 200.00 K Increased by +N/A% | -4.36 M Increased by +46.85% | Decreased by -2.18 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -3.99 M Increased by +30.58% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 175.00 K Increased by +N/A% | -7.78 M Decreased by -28.92% | Decreased by -4.44 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.17 M Increased by +49.76% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.21 M Increased by +75.53% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 50.00 K Decreased by -18.03% | -5.75 M Increased by +84.94% | Decreased by -11.49 K% Increased by +81.63% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -6.03 M Increased by +64.62% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -6.31 M Increased by +49.88% | Decreased by N/A% Decreased by N/A% |